**Please add the following new claims 117-130:**

117. (new) A method for treating or preventing an anemic condition in a subject, the method comprising administering to the subject a therapeutic amount of a recombinant erythropoietin produced in baby hamster kidney cells, the recombinant erythropoietin being other than Epoetin Alfa or Beta, wherein the amount of recombinant erythropoietin administered is selected to provide a therapeutic benefit within a treatment period, and wherein prior treatment of the subject with a therapeutic amount of Epoetin Alfa or Beta produced an adverse effect in the subject.

118. (new) The method of claim 117 wherein the adverse effect is selected from the group consisting of hypertension, headache, arthralgia, nausea, edema, fatigue, diarrhea, vomiting, chest pain, skin rash, dizziness, thrombosis and increased blood platelets.

119. (new) The method of claim 117 wherein the recombinant erythropoietin is administered at a dose of about 5 to about 150 IU/Kg, one to three times per week.

120. (new) The method of claim 117 wherein the recombinant erythropoietin is administered at a dose of about 10 to about 100 IU/Kg, one to two times per week.

C2

121. (new) The method of claim 117 wherein the recombinant erythropoietin is administered at a dose of about 10 to about 75 IU/Kg, one to two times per week.

122. (new) The method of claim 117 wherein the recombinant erythropoietin is administered at a dose of about 25 to about 60 IU/Kg, two times per week.

123. (new) The method of claim 117 wherein the recombinant erythropoietin is administered at a dose of about 25 to about 35 IU/Kg, two times per week.

124. (new) The method of claim 117 wherein the recombinant erythropoietin is administered at a dose of about 75 to about 150 IU/Kg, once per week.

125. (new) The method of claim 117 wherein the recombinant erythropoietin is administered at a dose of about 75 to about 100 IU/Kg, once per week.

126. (new) The method of claim 117 wherein the treatment period includes a titration period and the recombinant erythropoietin is administered at an initial dose of about 50 to about 100 IU/Kg per week during the titration period and is adjusted by about 5 to about 25 IU/Kg/week to obtain a hemoglobin count of about 10 to about 12 g/dl.

127. (new) The method of claim 117 wherein the treatment period further includes a maintenance period, and the recombinant erythropoietin is administered at a dose of about 40-60 IU/Kg per week during the maintenance period.

C2 128. (new) The method of claim 117 wherein the erythropoietin is Epoetin Omega.

129. (new) The method of claim 117 wherein the anemic condition is an anemia associated with a renal condition.

130. (new) The method of claim 117 wherein the therapeutic benefit is selected from the group consisting of increased RBC, increased HCT, increased hemoglobin, and increased vigor.